All lobbying filings

Washington Advocacy Group

Washington Advocacy Group filed a Q2 termination report for Amgen Inc. on June 12, 2026, reporting $5,000 in lobbying income.

Lobbying for Amgen Inc. · Biotechnology

As filed: WASHINGTON ADVOCACY GROUP for AMGEN INC.

All filings by Washington Advocacy Group · Everything Amgen Inc. has reported

Filing · LD-2 quarterly report Q2 termination

Reporting period

2nd Quarter 2026

Apr 1 - June 30 · Posted Jun 12, 2026

Income

$5,000

What the client paid this registrant for the period.

Client based in

District of Columbia

Representation ended

Jun 12, 2026

The registrant reported terminating its work for this client.

Official filing document

Government bodies contacted 1

SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 1

Health Issues

Monitor healthcare regulations and statutes and educate members of Congress on issues with regard to client's interests

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.